(Q33913192)

30 July 2017

1 reference

title

Cardiac myosin activation part 1: from concept to clinic (English)

1 reference

30 July 2017

Fady I Malik

1

1 reference

30 July 2017

Bradley P Morgan

series ordinal

2

1 reference

30 July 2017

publication date

17 May 2011

1 reference

Journal of Molecular and Cellular Cardiology

30 July 2017

published in

1 reference

30 July 2017

volume

51

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

454-461

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

30 July 2017

1 reference

Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Clinical practice. Systolic heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Cardiac-resynchronization therapy for the prevention of heart-failure events.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Inotropes in the management of acute heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Mechanisms and use of calcium-sensitizing agents in the failing heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Effects of pimobendan on the L-type Ca2+ current and developed tension in guinea-pig ventricular myocytes and papillary muscle: comparison with IBMX, milrinone, and cilostazol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Troponin as the Ca++-receptive Protein in the Contractile System*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Role of Ca2+ channel in cardiac excitation-contraction coupling in the rat: evidence from Ca2+ transients and contraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Alterations in left ventricular diastolic function in conscious dogs with pacing-induced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Structural and functional insights into the Myosin motor mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Effects of cardiac myosin isoform variation on myofilament function and crossbridge kinetics in transgenic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Mechanism of adenosine triphosphate hydrolysis by actomyosin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Electron cryo-microscopy shows how strong binding of myosin to actin releases nucleotide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Allosteric activators of glucokinase: potential role in diabetes therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Turning enzymes ON with small molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

Kinetic and equilibrium analysis of the myosin ATPase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.05.006

10.1016/J.YJMCC.2011.05.006

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference